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The human heme enzymes tryptophan 2,3-dioxygenase (hTDO) and indoleamine 2,3
dioxygenase (hIDO) catalyze the initial step in L-tryptophan (L-Trp) catabolism, the
insertion of dioxygen into L-Trp. Overexpression of these enzymes causes depletion of
L-Trp and accumulation of metabolic products, and thereby contributes to tumor immune
tolerance and immune dysregulation in a variety of disease pathologies. Understanding
the assembly of the catalytically active, ternary enzyme-substrate-ligand complexes is
not yet fully resolved, but an essential prerequisite for designing efficient and selective
de novo inhibitors. Evidence is mounting that the ternary complex forms by sequential
binding of ligand and substrate in a specific order. In hTDO, the apolar L-Trp binds first,
decreasing active-site solvation and, as a result, reducing non-productive oxidation of the
heme iron by the dioxygen ligand, which may leave the substrate bound to a ferric heme
iron. In hIDO, by contrast, dioxygen must first coordinate to the heme iron because a
bound substrate would occlude ligand access to the heme iron, so the ternary complex
can no longer form. Consequently, faster association of L-Trp at high concentrations
results in substrate inhibition. Here, we summarize our present knowledge of ternary
complex formation in hTDO and hIDO and relate these findings to structural peculiarities
of their active sites.
Keywords: indoleamine 2, 3-dioxygenase, tryptophan dioxygenase, flash photolysis, self-inhibition, ternary
complex formation, active-site hydration
INTRODUCTION
L-tryptophan (L-Trp) is an essential amino acid for mammals (Palego et al., 2016). Most of the
dietary L-Trp is metabolized via the kynurenine pathway (Stone and Darlington, 2002); its final
product, nicotinamide adenine dinucleotide (NAD+), plays a critical role in a wide range of cellular
reactions (Dölle et al., 2013). The first and rate-limiting step in the kynurenine pathway is the
introduction of both atoms of dioxygen (O2) into the pyrrole ring of the L-Trp indole side chain
(Figure 1A). The resulting shortage of L-Trp as well as the generated kynurenine metabolites affect
the activity of the mammalian reproductive, immune, and central nervous systems (Ball et al.,
2014).
Already in 1931, it was acknowledged that kynurenine is exclusively produced from
tryptophan (Kotake, 1931). At present, it is well-established that two structurally distinct heme
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FIGURE 1 | Schematics of ternary complex formation in hIDO1 and hTDO. (A) L-Trp oxidation reaction catalyzed by IDO and TDO. (B) View onto the ternary
hTDO–O2-L-Trp protein-ligand-substrate complex (pdb code 5TIA). hIDO1 and hTDO residues that anchor the L-Trp substrate (blue) are indicated in orange and
green, respectively. (C) Ternary complex formation in hTDO requires sequential binding of the L-Trp substrate and the O2 ligand. If O2 binds first, the heme is oxidized
and, therefore, cannot bind another O2 ligand. Instead, it may even coordinate a substrate molecule. (D) Ternary complex formation in hIDO1 requires sequential
binding of ligand and substrate. If L-Trp binds first, O2 access to the heme iron is blocked and the ternary complex cannot form (self-inhibition).
proteins—tryptophan 2,3-dioxygenase (TDO) and indoleamine
2,3-dioxygenase (IDO)—catalyze this oxidation reaction (Rafice
et al., 2009; Millett et al., 2012; Geng and Liu, 2014). The
analogous enzymes are induced differently and have different
tissue/cellular expression in mammals. In some organisms, their
genes have undergone duplication, leading to multiple isoforms
(Ball et al., 2014). Tetrameric TDOs, which are mainly found in
the liver as well as in some cancer cells (Opitz et al., 2011), are
generally highly selective for L-Trp (Millett et al., 2012; Geng
and Liu, 2014). Monomeric IDOs are widely distributed in all
tissues except the liver, where they can oxidize a broad range of
indoleamine derivatives (Rafice et al., 2009).
A recent summary of the early literature on TDOs and
IDOs from bacterial and mammalian sources (Raven, 2017) has
illustrated that, even after more than 70 years of research, there
is no agreement yet on the molecular details of the catalytic
reaction. In fact, the enzymes may not even share a common
mechanism because crystallographic, spectroscopic, kinetic, and
theoretical studies revealed distinct structural and functional
differences. However, independent of the detailed mechanism,
both enzymes require formation of the ternary Fe(II)–O2-L-Trp
complex to initiate the catalytic reaction. Here we will present our
present knowledge of the molecular structure of these complexes
and the dynamics of complex formation, and we will discuss their
impact on enzyme function.
OVERALL ENZYME STRUCTURE
TDOs comprise four subunits of ∼190 kDa (in total) in
eukaryotes and ∼120 kDa in prokaryotes. Based on the X-ray
structures of X. campestris TDO (xcTDO) and Ralstonia
metallidurans TDO (RmTDO), tetrameric TDO can be
considered as a dimer of dimers because part of the substrate
binding pocket of one subunit is formed by residues from an
adjacent subunit (Forouhar et al., 2007; Zhang et al., 2007). The
structure of the binary xcTDO–L-Trp complex suggests that
TDOs are induced-fit enzymes (Forouhar et al., 2007). Upon
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recognition of the L-Trp substrate, an extensive network of
interactions forms, stabilizing the substrate in the active site. In
particular, the αJ–αK loop, which is disordered in substrate-free
xcTDO, folds onto the active site, thus forming walls of the
substrate binding pocket that shield it from the solvent. An
alternative position of L-Trp, with the indole side chain not
so deep in the pocket and a still disordered αJ-αK loop, may
reflect an initial stage of ternary complex formation. The crystal
structure of substrate-free, ferric RmTDO shows that the flexible
αJ-αK loop can be highly ordered even in the absence of a
substrate molecule (Zhang et al., 2007). The recently reported
x-ray structure of a ternary complex, hTDO–O2-L-Trp, is in
excellent agreement with the binary xcTDO–L-Trp induced-fit
complex (Lewis-Ballester et al., 2016). Importantly, it confirms
the involvement of the αJ–αK loop in stabilizing the substrate.
Monomeric hIDOs have a molecular mass of∼45 kDa. In the
crystal structure of the hIDO1 isoform, the polypeptide chain
folds into two domains which are connected by a long loop
(Sugimoto et al., 2006). The surprisingly hydrophobic active site
hosting the heme prosthetic group is created by four helices of
the large domain and covered by the small domain and the loop.
The heme vicinity entirely lacks polar residues that could interact
with the heme-bound ligand. A part of the polypeptide chain,
comprising residues 360–380, could not be resolved, suggesting
that this stretch is highly flexible. A non-competitive inhibitor
of hIDO1, 4-phenyl-imidazole, binds directly to the heme iron
(Sono, 1989). Recent crystal structures of hIDO1 complexed
with various designed inhibitors also showed them coordinated
directly to the heme iron (Tojo et al., 2014; Wu et al., 2017). As of
today, no direct information exists as to how L-Trp is stabilized
in hIDO1.
ACTIVE-SITE RESIDUES INVOLVED IN
SUBSTRATE BINDING
The crystal structure of the hTDO–O2-L-Trp complex shows
how the L-Trp substrate is anchored in hTDO (Lewis-Ballester
et al., 2016). The imidazole side chain of the active-site histidine,
His76, is hydrogen-bonded to the N1 atom of the L-Trp indole
ring and, thereby, keeps it away from the ligand binding site
(Figure 1B). The L-Trp carboxylate is stabilized by bidentate ion-
pair interactions with the Arg144 side chain. The hydroxyl group
of the Thr342 side chain and one of the two heme propionates are
hydrogen-bonded to the L-Trp ammonium ion. Of note, Thr342
is part of the αJ–αK loop. It flanked by glycine residues (–Gly341-
Thr342-Gly343-Gly344–) that render this part of the loop highly
flexible (Álvarez et al., 2016).
In hIDO1, Ser167, Arg231, and Thr379 correspond to residues
His76, Arg144, and Thr 342 in hTDO, respectively (Figure 1B).
Based on comparison of the catalytic activities of different hIDO1
mutants, it was proposed early on that, among others, residues
Ser167 and Arg231 may play critical roles in L-Trp binding in
hIDO1 (Sugimoto et al., 2006). Substrate stabilization by Ser167
was excluded later (Chauhan et al., 2008), the involvement of
Arg231, however, was confirmed (Chauhan et al., 2012; Nienhaus
et al., 2017b). The essential role of Thr379, which could not be
inferred from the early X-ray structure (Sugimoto et al., 2006)
was revealed by kinetic studies (Álvarez et al., 2016) and also
by infrared spectroscopy (Nienhaus et al., 2017b). In recent X-
ray structures of hIDO1 complexed with the NLG919 substrate
analog (PDB IDs: 5EK2.B, 5EK3.B; Peng et al., 2016), the Thr379
Cα atom is ∼13 Å away from the heme iron, implying that
major conformational changes are required to bring Thr379
close to the substrate. Such large-scale motions can occur in
many proteins and are often required for functional processes
(Nienhaus et al., 1997). Replica exchange molecular dynamics
simulations of hIDO1 loop dynamics have indicated that such
structural changes are feasible (Álvarez et al., 2016).
Bound L-Trp slows carbon monoxide (CO) association in
IDO but accelerates it in TDO (Batabyal and Yeh, 2007),
suggesting that the exact orientation of the substrate with respect
to the heme-bound ligand must be different in the two enzymes.
In heme proteins, such structural details can be investigated by
using CO as sensitive probe of electric fields at the active site,
created by charges in the CO vicinity. For CO bound to a heme
iron, the stretching frequency, νCO, is typically in the 1,900–2,000
cm−1 spectral region (Nienhaus and Nienhaus, 2008) and varies
with the heme iron-ligand bond strength and the local electric
field (Braunstein et al., 1993; Li et al., 1994; Vogel et al., 1999).
Infrared spectra of CO-ligated hTDO and hIDO1 have shown
that L-Trp binding results in opposing shifts of the stretching
absorption of the heme-bound CO (Nickel et al., 2009; Nienhaus
et al., 2017b), implying a markedly different orientation of L-
Trp in the active site. In hTDO, there is a negative partial charge
near the CO oxygen, increasing νCO (Figure 2A), whereas there
is positive partial charge near the CO oxygen in hIDO1, which
has the opposite effect and shifts νCO downward (Figure 2E). It
has been suggested that the π-electron system of the aromatic
indole ring is in close proximity to the heme-bound CO in hTDO,
whereas the NH group of the L-Trp indole ring forms a H-bond
with the heme-bound CO in hIDO1 (Batabyal and Yeh, 2007).
Subsequently, however, it was realized that the heme-bound
ligand in hIDO1 is primarily stabilized by a hydrogen bond to
the terminal ammonium group of the substrate (Davydov et al.,
2010).
TERNARY COMPLEX FORMATION IN
hTDO AND hIDO1
X-ray crystallography only provides an average structure of the
catalytically active, ternary Fe(II)–O2-L-Trp complex but does
not reveal how the complex is formed. Currently, evidence is
mounting that binding of ligand and substrate occurs in a specific
sequence, with hTDO coordinating L-Trp first and then O2 and
hIDO1 in the opposite way (Figures 1C,D). Already in 1970,
Hayaishi and coworkers (Ishimura et al., 1970) observed that
ferrous Pseudomonas fluorescens TDO did not readily bind O2
in the absence of L-Trp, but was instead oxidized to the ferric
state. Later, it was concluded that L-Trp must bind first for
TDO to remain in the active, ferrous state (Sono et al., 1996).
Unlike hTDO (Basran et al., 2008), hIDO1 forms a stable oxy-
ferrous adduct also in the absence of L-Trp (Chauhan et al.,
Frontiers in Molecular Biosciences | www.frontiersin.org 3 January 2018 | Volume 4 | Article 94
Nienhaus and Nienhaus Catalytic Complex Formation in hIDO1 and hTDO
FIGURE 2 | Steady state infrared and UV/visible time-resolved spectroscopy on CO-ligated hTDO and hIDO1. (A–D) hTDO-CO. (E–H) hIDO1-CO. (A,E) Fourier
transform infrared absorption spectra of L-Trp-free (hTDO, green; hIDO1, orange) and L-Trp-bound (blue) CO-ligated enzymes at 4K. (B–H) Flash photolysis on
hTDO-CO and hIDO1-CO. Blue and red arrows indicate the direction of increasing L-Trp and CO concentration, respectively. Closed (open) symbols indicate data
taken in buffer (glycerol/buffer), without (hTDO, green; hIDO1, orange) and at saturating concentrations of L-Trp (blue). Vertical lines mark the time points of fast and
slow rebinding processes. (B,F) Rebinding kinetics (in buffer) as a function of L-Trp concentration. (C,G) Rebinding kinetics [in 75/25% (v/v) glycerol/buffer] as a
function of L-Trp concentration. All traces have been scaled to 1 at 1 µs. (D,H) Flash photolysis kinetics as a function of CO concentration. The area between the
rebinding traces recorded at two different CO concentrations (in glycerol/buffer) are colored in red to demonstrate that the traces are not shifted parallel along the time
axis, as expected for bimolecular rebinding. (I) Kinetic schemes depicting the CO rebinding reactions in hTDO and hIDO1 after photolysis. Green and orange boxes,
rebinding reactions in L-Trp-free samples; blue boxes, rebinding reactions at saturating concentrations of L-Trp. Involved species are color-coded accordingly.
Generated based on data published in Nienhaus et al. (2017a) (A–D), Nickel et al. (2009) (E), and Weber et al. (2014) (F–H).
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2008). Therefore, in hIDO1, L-Trp binding must not necessarily
precede O2 binding to maintain the ferrous oxidation state of
the heme iron. In fact, Yeh et al. (Lu et al., 2010) observed
that cyanide-bound ferric hIDO has a much higher affinity
toward L-Trp than the ligand-free ferric enzyme. Additional
kinetic studies revealed that L-Trp binding was still favored
if the ferric enzyme was converted to the ferryl intermediate,
Fe4+-O2− (Lu and Yeh, 2011). Therefore, they concluded that
ligand binding to the heme iron of hIDO1 occurs first and
introduces conformational changes to facilitate subsequent L-
Trp binding. Sequential, ordered O2 and L-Trp binding was also
proposed by Raven and collaborators (Efimov et al., 2012). They
found that substrate binding increases the reduction potential of
the hIDO1 heme iron and, thereby, disfavors O2 binding.
Our group has investigated ternary complex formation in
hTDO and hIDO1 in great detail by using steady state and time-
resolved optical spectroscopy (Nickel et al., 2009; Nienhaus et al.,
2011, 2017a,b; Weber et al., 2014). In these experiments, we
have replaced O2 by CO because CO is not reactive toward L-
Trp, which provides us with the opportunity to observe ligand
and substrate dynamics in the heme pockets of the enzymes
in the absence of the ensuing enzymatic reaction. In our flash
photolysis experiments (Weber et al., 2014; Nienhaus et al.,
2017a), photodissociation of CO with a nanosecond laser pulse
generates a metastable pentacoordinate deoxy species, which
relaxes back to the CO-ligated form along different pathways.
In heme proteins, CO rebinding occurs with two distinct
mechanisms, geminate rebinding of ligands that have not escaped
from the protein and bimolecular rebinding of ligands from the
solvent to a deligated protein. Here we only focus on the large
fraction of CO molecules that bind to the heme iron on the
millisecond to second time scale in a bimolecular fashion, for
which the rate of association depends on the concentration of
the reactants. In the presence of a large excess of ligand, its
concentration remains constant during the rebinding reaction,
and exponential rebinding is observed, with an association
rate coefficient proportional to the ligand concentration. Our
observable is the temporal change of the laser-induced absorption
difference at a particular wavelength, which is proportional to the
fraction of enzymes, N(t), that have not yet rebound a ligand.
Ternary Complex Formation in hTDO
Selected CO rebinding traces of hTDO are displayed in
Figures 2B–D (Nienhaus et al., 2017a). Substrate-free hTDO-CO
dissolved in buffer solution shows two sequential rebinding steps
(Figure 2B, green), marked by vertical green lines, revealing co-
existence of two kinetically different species (Nienhaus et al.,
2017a). With increasing L-Trp concentration, the amplitude at
the earliest time (1 µs) decreases, indicating that bound L-Trp
partially interferes with CO escape from the enzyme (Figure 2B).
This variation can be described by an equilibrium binding curve
with a dissociation coefficient, Kd = 10 ± 1µM. Moreover,
the slow kinetic step gradually disappears until only a fast step
remains (Figure 2B, blue, marked by the left blue line). If the
hTDO-CO samples are prepared in glycerol/buffer, a slow step
persists even at saturating L-Trp concentrations (Figure 2C).
All these processes represent bimolecular CO binding
from the solvent because they accelerate with increasing CO
concentration (Figure 2D). However, the apparent association
rate coefficients extracted from exponential fits to the fast and
slow rebinding phases do not show a strictly linear correlation,
indicating that these processes do not represent bimolecular
rebinding only. Of note, for a bimolecular rebinding, the kinetics
should run strictly parallel. A careful quantitative analysis
has shown that, for both substrate-free and substrate bound
hTDO, the observed [CO]-dependent rebinding kinetics can be
described by a four-state kinetic model that includes exchange
between fast and slowly rebinding hTDO conformations, hTDOF
and hTDOS, in addition to CO recombination to these two
states (Figure 2I). The fast rebinding species have an active
site with facile ligand access to the heme iron. In the slowly
rebinding conformations, ligand access is greatly hindered.
We have proposed that the dominant, substrate-free species
corresponds to a structure with an open heme pocket that allows
solvent molecules to flood the active site, thereby slowing ligand
rebinding. Moreover, O2 entering such a solvated pocket will lead
to non-productive oxidation of the heme iron. Substrate binding
shifts the conformational equilibrium markedly toward the fast
species. The bulky, hydrophobic L-Trp amino acid reduces the
number of active site solvent molecules or perhaps removes them
entirely. In addition, L-Trp does not occlude the O2 binding site
at the heme iron. As a result, ligand access to the heme iron is
facilitated and the probability of iron oxidation is diminished.
Accordingly, substrate binding primes the active site for the
subsequent ligand binding step (Figure 1C).
Ternary Complex Formation in hIDO1
The effects of L-Trp on CO rebinding in hIDO1 are markedly
different. Without substrate, rebinding occurs in a single step
(Figure 2F, orange, marked by orange vertical line). With
increasing L-Trp concentration, the amplitude of the rebinding
trace at 1 µs decreases to ∼20% of the value obtained without L-
Trp, indicating that L-Trp binding strongly affects ligand escape,
i.e., it blocks the exit pathway (Weber et al., 2014). The L-
Trp concentration dependence of the kinetic amplitude can be
described by a binding curve with an equilibrium dissociation
coefficient, Kd = (95 ± 7) µM in buffer. Furthermore, rebinding
slows in the presence of substrate (Figure 2F, blue, compare
blue vertical line). The effect becomes even more obvious
with samples dissolved in glycerol/buffer (Figure 2G). Here, we
can clearly distinguish fast rebinding in substrate-free hIDO1
and slow rebinding in L-Trp-bound hIDO1. The rate of the
fast bimolecular rebinding step depends linearly on the CO
concentration, as expected for a pseudo-first-order bimolecular
reaction. In contrast, the kinetics of the slow step are not at
all affected by the CO concentration (Figure 2H), indicating
that CO rebinding is rate-limited by another process that is
independent of the CO concentration and precedes CO binding.
We have assigned this process to thermal dissociation of L-Trp.
Thus, L-Trp must leave the active site for CO to bind (Figure 2I).
As a result, the diatomic ligand, i.e., O2 in the physiological
context, has to bind first for successful ternary complex formation
(Figure 1D) (Weber et al., 2014).
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Sequential Binding in hIDO1 Causes
Self-Inhibition
Only during the last five years it was realized that sequential
binding can also account for hIDO1 self-inhibition, i.e.,
inhibition of the enzyme in the presence of high substrate
concentrations. Initially, it was believed that L-Trp binds directly
to the ferric heme iron at high concentrations and thereby
inhibits heme iron reduction to its active ferrous state (Sono et al.,
1980). Subsequently, substrate inhibition was considered to result
from the binding of a second L-Trp molecule in an inhibitory
substrate binding site (Lu et al., 2009, 2010; Nickel et al., 2009;
Nienhaus et al., 2011). In 2012, Raven et al. (Efimov et al.,
2012) suggested that the ordered sequential binding of O2 and
L-Trp already suffices to cause self-inhibition: L-Trp association
is slow at low L-Trp concentration, and, therefore, O2 is likely
to bind first. At high L-Trp concentrations, the binding order
can be reversed; L-Trp binds first, increases the heme reduction
potential and thus disfavors subsequent O2 binding. Our kinetic
experiments on ternary hIDO1–CO–L-Trp complex formation
have confirmed that sequential binding is indeed sufficient to
account for self-inhibition (Weber et al., 2014). Changes in the
heme reduction potential and also binding of a second L-Trp
cannot be excluded but are not necessary for the process. At
high L-Trp concentrations, the bulky substrate is likely to bind
prior to the O2 ligand, thereby suppressing ligand access to the
heme iron and preventing formation of the catalytically active
complex. In this case, the enzymatic activity is rate-limited by L-
Trp dissociation. Of note, self-inhibition may well be incomplete
at physiologically relevant L-Trp concentrations if there is a small
probability that ligands can bypass the bulky substrate (Kolawole
et al., 2015).
THE ROLE OF THE ACTIVE-SITE
HISTIDINE IN TERNARY COMPLEX
FORMATION
Our kinetic studies have suggested that active-site hydration plays
a key role in ternary complex formation in hTDO, but not in
hIDO1. The hTDO active-site histidine residue, His76, is likely
to be the moiety causing this difference (Thackray et al., 2008).
This histidine may control the water content of the substrate-free
xcTDO active site and prevent formation of the nonproductive
ferric enzyme-substrate complex. hIDO1 is lacking this polar
residue and, therefore, is less likely to attract water molecules
to the heme pocket. To confirm this critical role of His76, we
compared the flash photolysis kinetics on CO-ligated enzyme
mutants, His76Ala hTDO and Ser167His hIDO1. In His76Ala
hTDO, CO rebinding is dramatically accelerated with respect to
the wild-type protein (Nienhaus et al., 2017a), indicative of a
readily accessible heme iron and thus a much lower degree of
solvation. Replacing Ser167 in hIDO1 by a histidine results in
two-step CO rebinding, with a very slow second step (Nienhaus
et al., 2017b) and a dramatic destabilization of the ferrous-oxy
complex (Chauhan et al., 2008), indicative of increased solvation.
Overall, it appears that a single amino acid residue may be
responsible for the different sequences in hIDO1 and hTDO
ternary complex formation.
OUTLOOK
Here we have presented a brief account of the differences between
two Trp-processing enzymes, hTDO and hIDO1, in regard to
ternary complex formation, which is a key step in the catalytic
process. Recent studies have found that hTDO and hIDO can
be expressed in different regions of the same tumor, suggesting
that these enzymes may not be redundant but rather may play
different roles in tumor development (Yu et al., 2017). It is
evident that the design of highly selective and efficient inhibitors
will greatly benefit from further advances in unraveling the
mechanistic details of ternary complex formation in hIDO and
hTDO.
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